Compare AstraZeneca plc (AZN) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Illinois Tool Works Inc. — how do they compare? AstraZeneca plc trades at $168.98 (market cap $253.13B), while Illinois Tool Works Inc. trades at $269.74 (market cap $78.33B). The key difference: AstraZeneca plc is far larger — about 3.2× Illinois Tool Works Inc.'s market cap, and Illinois Tool Works Inc. pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| AZN | ITW | |
|---|---|---|
Market Cap | $253.13B | $78.33B |
Sector | Health | Industrials |
52-Week High | $209.48 | $299.60 |
52-Week Low | $137.44 | $241.07 |
Enterprise Value | $279.37B | $86.66B |
Dividend Yield | 1.92% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Illinois Tool Works (ITW) trades at $271.50, up 1.0% today, with a bullish technical signal from moving averages and a consensus analyst price target of $288.25. The company has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.66 versus $2.57 expected, and maintains strong profitability with a net income margin of 19.32% and ROE of 96.88%. Recent news highlights segment strength and a declared quarterly dividend of $1.61.
The outlook for ITW is positive, supported by earnings momentum and operational efficiency, though risks include construction sector weakness and currency headwinds. The stock offers a balanced opportunity with solid fundamentals and a dividend, but investors should weigh high valuation multiples against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
